It will be used with the company's Ceprate SC Stem Cell Concentration System to reduce the number of B cells in mobilized peripheral blood used for autologous hematopoietic transplantation in patients with relapsed non-Hodgkin's lymphoma...The proposed label expansion says selection of peripheral blood stem cells results in a greater than 100-fold reduction in the number of tumor cells present in the autograft

stem cell technologies that allow the precise genetic modification of all avian species, including commercial poultry

The multiyear deal gives ZymoGenetics a subscription to the database that corresponds to a library of mutant mouse embryonic stem cell clones

The gene therapy involves removal of patients immune and stem cells, treatment with Enzo's StealthVector to make them HIV resistant, and reinfusion to generate more HIV-resistant cells. * Liposome Co., of Princeton, N.J., entered an agreement with American Home Products Corp., of Madison, N.J., to market Liposome's Abelcet in Denmark, Finland, Iceland, Norway and Sweden

The six-month grant will support the establishment of an effective one-step protocol for the enrichment or purification of blood stem cells...The company has discovered a blood stem cell marker called glycoprotein 105. * Vertex Pharmaceuticals Inc., of Cambridge, Mass., presented preliminary 12-week data from an ongoing Phase II study of 141W94 (VX-478) at the Sixth European Conference on Clinical Aspects and Treatment of HIV-infection, in Hamburg Germany

RiboGene will use its genomics expertise to identify targets for therapeutic compounds developed by ArQule. * CellPro Inc., of Seattle, applied to the FDA to expand the label of its Ceprate SC Stem Cell Concentration System to include selection of peripheral blood stem cells

Two of the company's products use encapsulated cell implants to deliver growth factors and neural stem cells, replacing neural tissue damaged by disease or injury. * CytRx Corp., of Atlanta, received a grant from the FDA's division of orphan drug development to support the company's upcoming study of Flocor, used to treat sickle-cell patients undergoing acute vaso-occlusive crises

One grant from the National Heart, Lung and Blood Institute will fund studies into therapeutic uses of stem cells derived from umbilical cord blood and the other will explore a suicide gene therapy for AIDS in which patients' healthy cells would die when infected with HIV, preventing the virus from replicating. * Biogen Inc., of Cambridge, Mass., said it will repurchase 2.5 million shares of its common stock over the next two years. * Medicines Co., of Cambridge, Mass., said Phase II results

Aastrom's cell production system will be used to produce ex vivo stem cells from a small amount of umbilical cord blood for transplant to 30 adults and children for whom no matched bone marrow donors were found. * Bio-Technology General Corp., of Iselin, N.J., said a Phase I trial of a deep vein thrombosis (DVT) diagnostic, employing the company's genetically engineered fibrin binding domain (FBD) peptide, was begun by Draxis Health Inc., of Mississauga, Ontario, which licensed the peptide

Geron's research on primordial stem cells, which are formed early in human embryonic development, will focus on analyzing genes linked to cell differentiation...Geron also is working with the University of California, San Francisco, on human primordial stem cells, and with the University of Wisconsin, Madison, on nonhuman primate primordial stem cells. * Hybridon Inc., of Cambridge, Mass., began a Phase I trial of oral GEM 92, a second-generation antisense drug for AIDS

Lexicon has developed an Omnibank library of thousands of mouse embryonic stem cell clones catalogued by the gene mutated in each clone

The acquisition is expected to allow CytoTherapeutics to accelerate the development of a new category of human neural stem cell product candidates and enhance the development of CytoTherapeutics' lead product for chronic pain

The ligand, also under development as a stem cell mobilizer, may potentially be used as a vaccine adjuvant to treat cancer and infectious diseases. * Lidak Pharmaceuticals, of La Jolla, Calif., completed a Phase I/II clinical trial of large multivalent immunogen vaccine, LP2307, in Stage III and IV malignant melanoma patients

Activated Cell Therapy Inc., of Mountain View, Calif., has signed a collaboration agreement with Osiris Therapeutics Inc., of Baltimore, which gives the latter company exclusive worldwide rights to use ACT's proprietary cell isolation and enrichment technology specifically for the recovery of mesenchymal stem cells

Baxter International Inc., of Deerfield, Ill., and two associates have asked a federal court in Delaware to issue a permanent injunction against sales of Bothell, Wash.-based CellPro Inc.'s Ceprate SC Stem Cell Concentration System, which was approved by the FDA in December 1996

The treatment involves inserting ribozymes into stem cells that replenish immune system cells

The drug is targeted initially for boosting stem cells production of blood

DLK, the company said, is part of a family of proteins that keep cells in an undifferentiated state and may have applications for expanding stem cells for use in bone marrow transplants and gene therapy. * Immune Response Corp., of Carlsbad, Calif., said Spain's Ministry of Health will conduct a Phase II trial of Remune, the company's HIV therapeutic vaccine, in combination with antiviral drugs to treat AIDS

The FDA told Gensia a scheduled October 1996 review of GenESA by the FDA's Cardiovascular and Renal Drugs Advisory Committee may not be necessary. * Geron Corp., of Menlo Park, licensed technology from GenPharm International, of Mountain View, Calif., for genetically altering primate primordial stems cells for use in treating age-related diseases...The technology involves modification of the stem cells prior to transplanting them